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Abstract
Objective: To assess asthma patients in Brazil in terms of the level of asthma control, compliance with 
maintenance treatment, and the use of rescue medication. Methods: We used data from a Latin American 
survey of a total of 400 asthma patients in four Brazilian state capitals, all of whom completed a questionnaire 
regarding asthma control and treatment. Results: In that sample, the prevalence of asthma was 8.8%. Among 
the 400 patients studied, asthma was classified, in accordance with the Global Initiative for Asthma criteria, as 
controlled, partially controlled, and uncontrolled in 37 (9.3%), 226 (56.5%), and 137 (34.3%), respectively. In 
those three groups, the proportion of patients on maintenance therapy in the past four weeks was 5.4%, 19.9%, 
and 41.6%, respectively. The use of rescue medication was significantly more common in the uncontrolled 
asthma group (86.9%; p < 0.001). Conclusions: Our findings suggest that, in accordance with the established 
international criteria, asthma is uncontrolled in the vast majority of asthma patients in Brazil. Maintenance 
medications are still underutilized in Brazil, and patients with partially controlled or uncontrolled asthma are 
more likely to use rescue medications and oral corticosteroids. 
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Resumo
Objetivo: Avaliar pacientes asmáticos no Brasil em relação ao grau de controle da asma, a aderência ao tratamento 
de manutenção e o uso de medicação de alivio em pacientes asmáticos. Métodos: Foram utilizados os dados de 
um inquérito latino-americano, obtidos em quatro capitais brasileiras, de 400 pacientes com asma através de um 
questionário sobre o controle e o tratamento da doença. Resultados: A prevalência de asma nesta amostra foi de 
8,8%. Dos 400 pacientes estudados, 37 (9,3%), 226 (56,5%) e 137 (34,3%), respectivamente, foram classificados, 
segundo critérios da Global Initiative for Asthma, como tendo asma controlada, parcialmente controlada e não 
controlada. A proporção de pacientes em terapia de manutenção nas últimas quatro semanas naqueles três 
grupos, respectivamente, foi de 5,4%, 19,9% e 41,6%. O uso de medicação de alivio foi significativamente mais 
comum nos pacientes com asma não controlada (86,9%; p < 0,001). Conclusões: Nossos achados sugerem que 
a grande maioria dos pacientes com asma no Brasil não apresenta sua doença controlada segundo critérios 
internacionais. As medicações de manutenção ainda são subutilizadas no Brasil, e o uso de medicações de 
alívio e corticoide oral é mais frequente em pacientes com asma parcialmente controlada ou não controlada. 
Descritores: Asma/terapia; Asma/prevenção e controle; Adesão à medicação.
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Introduction
Asthma is a worldwide, common chronic disease 
that affects individuals of all ages and has a great 
influence on patient quality of life. (1,2) In 2006, 
the International Study of Asthma and Allergies in 
Childhood reported that, in Brazil, the prevalence 
of asthma was 24.3% in schoolchildren and 19.0% 
in adolescents,(3,4) whereas the prevalence of 
physician-diagnosed asthma was approximately 
10%. Because of its high prevalence, asthma has 
a major socioeconomic impact,(5) given that, when 
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Methods
In 2011, the LA AIM survey, conducted in 
five Latin American countries (Argentina, Brazil, 
Mexico, Venezuela, and Puerto Rico), was designed 
using the same methods as the Asthma Insight 
and Management Study (AIM) conducted in the 
United States.(16) The present study is based on 
the analysis of the Brazilian data from the LA 
AIM survey.
In Brazil, 4,545 households were randomly 
selected from a national probability sample in four 
cities: São Paulo; Rio de Janeiro; Curitiba; and 
Salvador. The population surveyed consisted of 
adults over 18 years of age and parents/caregivers 
of adolescents between 12 and 17 years of age; 
the individuals selected should have physician-
diagnosed asthma. After the households that were 
initially selected were contacted by phone, 400 
asthma patients were selected to be interviewed 
in person. The interviews lasted a maximum 
of 35 min. The questionnaire consisted of 53 
questions that addressed five asthma topics: 
symptoms; impact of asthma on daily activities; 
perception of asthma control; exacerbations; 
and treatment and medications.
The questions about symptoms covered daytime 
and nighttime symptom frequency in the past 
four weeks, symptom frequency during the worst 
month of the past 12 months, the most bothersome 
symptom, triggering symptoms, symptom 
seasonality, and the frequency of symptom 
worsening. Respondents were asked whether they 
or their children had sought medical attention 
during exacerbations, symptom worsening, or 
severe acute episodes in the past year.
Regarding treatment, respondents were 
asked about the use of maintenance and rescue 
medications in the past four weeks and whether 
their physician had provided a written action 
plan for asthma management. Patients were 
investigated as to whether they used maintenance 
medication every day, whether that medication 
was necessary when the symptoms were not 
present, and whether rescue medication could 
be used every day, if necessary.
The present study was approved by the Research 
Ethics Committee of the Federal University of São 
Paulo Hospital São Paulo (Ruling no. 250155).
Statistical analysis
Categorical data are presented as absolute 
values and percentages, and continuous data 
it is uncontrolled, it can lead to hospitalizations 
and school/work absenteeism, as well as being 
life threatening during attacks.(6-9)
Although there have been effective medications 
for the treatment of asthma since the 1980s, 
complete symptom control is not achieved in most 
patients.(10,11) Because of their anti-inflammatory 
activity, inhaled corticosteroids are the therapy of 
choice in asthma. Maintenance treatment with 
an inhaled corticosteroid reduces the frequency 
and severity of exacerbations and the number 
of hospitalizations and emergency room visits, 
as well as improving quality of life, pulmonary 
function, and bronchial hyperresponsiveness and 
decreasing exercise-induced bronchoconstriction.(2) 
Despite all the known benefits of this treatment, 
the Asthma Insights and Reality in Latin America 
(AIRLA) survey reported that only 6% of the asthma 
patients were using an inhaled corticosteroid.(12) 
Inadequate maintenance treatment has a direct 
influence on the rate of disease control. Many 
studies have shown that, even in the 2000s, only 
one third of the asthma patients had totally 
controlled asthma.(13,14) In the AIRLA survey, 
only 2.6% of the patients had well-controlled 
asthma.(12)
Several guidelines have been published to 
disseminate the appropriate management of 
asthma, on the basis of current clinical evidence.(2,8) 
They contain objective strategies for assessing and 
measuring asthma control, as well as therapeutic 
recommendations and plans for asthma-related 
education. Those guidelines are expected to make 
it possible to reduce the impact of asthma on 
the lives of patients and to achieve complete 
asthma control.
In 2011, the Latin America Asthma Insight and 
Management (LA AIM) survey(15) was designed 
to assess the impact of asthma on the lives of 
patients, their perception of their symptoms, and 
the prescribed treatment for the disease. The 
results of that survey made it possible to assess 
asthma control in those patients in accordance 
with the Global Initiative for Asthma (GINA) 
guidelines.(8)
The present study analyzed the data collected 
by the LA AIM survey in Brazil in order to determine 
the medications used (maintenance and rescue 
medications) and compliance with treatment, 
as well as to relate these variables to the level 
of asthma control.
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acting β2 agonists) progressively increased as a 
function of poor asthma control, with 86.9% of 
the patients with uncontrolled asthma reporting 
their use (p < 0.001).
Oral corticosteroid use during an asthma attack 
was assessed in the past 12 months. The rates of 
oral corticosteroid use during an asthma attack 
were 45.9%, 40.7%, and 56.2%, respectively, in the 
controlled, partially controlled, and uncontrolled 
asthma groups, without significant difference 
(p = 0.06).
During the personal interview, participants 
reported what medications they had used for 
maintenance treatment of asthma and relief of 
symptoms in the past four weeks. Subsequently, a 
list of trade names of medications was presented 
to participants so that they could indicate the 
one(s) that they were using for maintenance 
treatment. The exact same list was presented 
to patients so that they could then identify the 
medication(s) used for relief of symptoms.
Most patients in the controlled asthma group 
reported that they were not using maintenance 
medication (55.6%), whereas among those in 
the partially controlled and uncontrolled asthma 
groups, the most commonly used medication was 
a short-acting bronchodilator (35.8% and 53.3%, 
respectively). Only 2.8% of the individuals in the 
controlled asthma group were using an inhaled 
corticosteroid, either alone or in combination 
with a long-acting β2 agonist. The rate of inhaled 
corticosteroid use was also very low in the partially 
controlled and uncontrolled asthma groups (12.9% 
and 24.1%, respectively). The use of a long-acting 
β2 agonist alone was reported by 5.6% and 3.5% 
of the patients in the controlled and partially 
controlled asthma groups, respectively. Only one 
are presented as mean and standard deviation. 
The chi-square test was used for the comparison 
of categorical data among the groups studied 
(controlled, partially controlled, and uncontrolled 
asthma), and ANOVA was used for the comparison 
of means. Tukey’s post hoc test was used. A value 
of p < 0.05 was considered statistically significant.
Results
The characteristics of the asthma patients in 
Brazil are shown in Table 1, by groups determined 
by GINA classification. In that Brazilian sample, 
the proportion of asthma patients was 8.8%. In 
accordance with the GINA criteria for asthma 
control, asthma was classified as controlled in 
37 patients (9.3%), as partially controlled in 226 
(56.5%), and as uncontrolled in 137 (34.3%).
The mean age was lower in the controlled 
asthma group than in the uncontrolled asthma 
group (31.1 ± 9.9 years vs. 39.3 ± 16.6 years; p 
= 0.03). In all groups, females predominated, 
especially in the uncontrolled asthma group 
(76.6%; p = 0.02). Most patients had pets, 
regardless of the group. In the controlled 
asthma group, 75.6% of the patients were never 
smokers. The presence or absence of smokers 
in the household did not affect asthma control 
(Table 1).
The medications used in the treatment of 
asthma are shown in Table 2. Regarding the use 
of maintenance medication in the past four weeks, 
94.6% of the patients with controlled asthma 
reported that they were not using any maintenance 
medication regularly, whereas 80.1% of those 
with partially controlled asthma and 58.4% of 
those with uncontrolled asthma stated the same 
(p < 0.001). The use of rescue medication (short-
Table 1 - Demographic and epidemiological data of the respondents.a
Variables Groups p
CA PCA UA
(n = 37) (n = 226) (n = 137)
Age, yearsb 31.1 ± 9.9 38.5 ± 16.4 39.3 ± 16.6 0.03*
Female gender 24 (64.9) 143 (63.3) 105 (76.6) 0.02
Pets 20 (54.1) 115 (51.3) 64 (46.7) 0.59
Smoking status     
Smoker 7 (18.9) 60 (26.5) 29 (21.2) 0.007
Former smoker 2 (5.4) 56 (24.8) 45 (32.8)
Never smoker 28 (75.7) 110 (48.7) 62 (45.3)
Smoker(s) in the household 14 (37.8) 101 (44.7) 57 (41.6) 0.67
CA: controlled asthma; PCA: partially controlled asthma; and UA: uncontrolled asthma. aValues expressed as n (%), 
except where otherwise indicated. bValues expressed as mean ± SD. *CA group vs. UA group.
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the patients said that it was a cause for concern, 
and, when categorized into groups, 51.3%, 57.5%, 
and 73.0% of the patients in the controlled, 
partially controlled, and uncontrolled asthma 
groups, respectively, reported that concern. The 
reasons given by patients for their fear of using 
an inhaled corticosteroid were its side effects, 
concern about its safety and long-term effects, 
and concern about dependence.
Discussion
The present study has shown that, in 
accordance with GINA criteria,(8) asthma is 
uncontrolled in the vast majority of asthma 
patients in Brazil. A small proportion of patients 
in the uncontrolled and partially controlled 
asthma groups used maintenance medication, 
and, consequently, they were the ones who used 
oral corticosteroids and rescue medication the 
most often in the past 12 months.
Because the inclusion criterion for the present 
study was having received a physician diagnosis 
of asthma, the observed proportion of asthma 
patients was 8.8%, which is very similar to the 
prevalence of physician-diagnosed asthma in 
Brazil, according to the International Study of 
Asthma and Allergies in Childhood.(17) Therefore, 
it is possible that our results reflect the national 
situation regarding asthma control. Nevertheless, 
the objective of the present study was not to 
assess the prevalence of asthma in Brazil, but 
rather to assess patient’s use of medications.
The poor control of asthma in Latin America 
has been known since 2003, when the AIRLA 
survey showed that asthma was totally controlled 
in only 2.6% of the adult patients with asthma 
and in 2.4% of the children with asthma.(12) The 
design of our study was similar to that of the 
AIRLA survey, and, although our study used other 
criteria for classifying asthma control (daytime and 
nighttime symptoms, exercise-induced symptoms, 
patient in the partially controlled asthma group 
reported using tiotropium (Table 3).
Regarding rescue medications, 12.1% and 
10.9% of the individuals in the controlled and 
partially controlled asthma groups, respectively, 
reported that they were not using any rescue 
medication. In contrast, all patients in the 
uncontrolled asthma group used at least one 
medication they referred to as rescue medication. 
The vast majority of patients in the three groups 
used a short-acting bronchodilator (66.7%, 71.5%, 
and 80.6% in the controlled, partially controlled, 
and uncontrolled asthma groups, respectively). 
An inhaled corticosteroid was considered rescue 
medication by some patients (3.0%, 2.3%, and 
4.5% in the same groups, respectively), as were 
the combination of an inhaled corticosteroid and 
a long-acting β2 agonist (0.0%, 3.2%, and 9.0%, 
respectively) and a long-acting β2 agonist alone 
(9.1%, 2.7%, and 0.0%, respectively; Table 4).
Those patients who had asthma attacks in the 
past 12 months were asked whether, during an 
attack, their use of rescue medication was higher 
than, lower than, or equal to their daily use. All 
groups reported an increased need to use rescue 
medication (30.0%, 64.9%, and 57.1% of the 
patients in the controlled, partially controlled, 
and uncontrolled asthma groups, respectively), 
although the increase was more pronounced in 
the partially controlled and uncontrolled asthma 
groups (p = 0.002 in relation to the controlled 
asthma group; data not shown in tables).
In the sample as a whole, 42.0% of the asthma 
patients reported that their physician had provided 
a written treatment action plan, explaining the 
need for maintenance treatment and when to 
use the rescue medication.
In addition, 41% of the patients reported 
that they fully or partially agreed with the idea 
that the rescue medication should be used daily, 
regardless of the presence of symptoms. Regarding 
continuous inhaled corticosteroid use, 62.3% of 
Table 2 - Medications used in the treatment of asthma by the patients in the groups studied.a
Variables Groups p
CA PCA UA
(n = 37) (n = 226) (n = 137)
Maintenance medication in the past 4 weeks 2 (5.4) 45 (19.9) 57 (41.6) < 0.001
Rescue medication in the past 4 weeks 5 (13.5) 98 (43.4) 119 (86.9) < 0.001
Oral corticosteroid in the past 12 months during an 
asthma attack
17 (45.9) 92 (40.7) 77 (56.2) 0.06
CA: controlled asthma; PCA: partially controlled asthma; and UA: uncontrolled asthma. aValues expressed as n (%).
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patients could be the reason for the lower rate of 
hospital visits and admissions among American 
patients with asthma. Likewise, the proportion 
of patients who used rescue medication in the 
United States was lower in all groups, which 
reinforces the idea that asthma is better controlled 
in patients who use maintenance medication 
more often.(18) A study conducted at a referral 
center for the treatment of pediatric asthma in 
Brazil reported that symptoms were controlled 
in 45% of the patients.(19) This shows us that, 
even at a referral center for the treatment of 
asthma, although the reported rate of disease 
control was much higher than that found in the 
present study, asthma control was achieved in 
only half of the patients.
In 2003, the rate of inhaled corticosteroid use 
in Latin America was 6%.(12) In the present study, 
15.8% of the patients had been on maintenance 
therapy in the past four weeks, when assessed by 
medication use. Although this rate is below ideal, 
with the ideal scenario being inhaled corticosteroid 
use by all patients with partially controlled or 
uncontrolled asthma, it is two and a half times 
higher than that reported by the AIRLA survey, 
demonstrating a significant improvement towards 
meeting the goal established in the guidelines. 
The low number of patients who used an inhaled 
corticosteroid could reflect two situations: 
physicians are not prescribing controller medication 
properly, which is in clear noncompliance with 
the Brazilian Thoracic Association guidelines(2) 
and the GINA guidelines;(8) or patients are poorly 
and overall severity of symptoms), the two studies 
showed similar results. The fact that the current 
number of patients with controlled asthma is 
approximately nearly three times that of 10 years 
ago, according to the AIRLA survey, should not 
be seen as encouraging, because, for a disease 
for which treatment and treatment effectiveness 
are well known, 8% is a very low number.
Despite widespread knowledge that inhaled 
steroids are the medication of choice as asthma 
controllers, we found that most patients did not 
use them. The fact that only 5.4% of the patients 
with controlled asthma had used maintenance 
medication in the past four weeks may reflect that 
this group consists of patients with mild disease, 
not requiring continuous inhaled corticosteroid 
use. However, approximately half of those patients 
had to take an oral corticosteroid during an 
asthma attack, which demonstrates that, at some 
time in the year, asthma was uncontrolled in 
those patients. Only 19.9% of the patients with 
partially controlled asthma and 41.6% of those 
with uncontrolled asthma reported that they 
had used maintenance medication in the past 
month, despite the fact that they reported rescue 
medication use. In the AIM survey conducted in the 
United States in 2009,(18) the observed proportion 
of patients who used maintenance medication 
in the controlled asthma group in that country 
(32%) was higher than that in Brazil. The fact 
that inhaled corticosteroids were used by a higher 
proportion of American patients than of Brazilian 
Table 3 - Maintenance mediations used for asthma 
control in the past four weeks according to the patients 
or their parents/guardians.a
Variables Groups
CA PCA UA
(n = 36) (n = 226) (n = 137)
None 20 (55.6) 81 (35.8) 20 (14.6)
Short-acting 
bronchodilator
12 (33.3) 81 (35.8) 73 (53.3)
Tiotropium 0 (0.0) 1 (0.4) 0 (0.0)
IC alone 1 (2.8) 11 (4.9) 12 (8.8)
LAB + IC 0 (0.0) 18 (8.0) 21 (15.3)
LAB alone 2 (5.6) 8 (3.5) 0 (0.0)
Aminophylline 0 (0.0) 6 (2.7) 4 (2.9)
Unknown 0 (0.0) 11 (4.9) 3 (2.2)
Others 1 (2.8) 9 (4.0) 4 (2.9)
CA: controlled asthma; PCA: partially controlled asthma; 
UA: uncontrolled asthma; IC: inhaled corticosteroid; and 
LAB: long-acting bronchodilator. aValues expressed as n (%).
Table 4 - Rescue medications used for asthma control 
in the past four weeks according to the patients or 
their parents/guardians.a
Variables Groups
CA PCA UA
(n = 33) (n = 221) (n = 134)
None 4 (12.1) 24 (10.9) 0 (0.0)
Short-acting 
bronchodilator
22 (66.7) 158 (71.5) 108 (80.6)
IC alone 1 (3.0) 5 (2.3) 6 (4.5)
LAB + IC 0 (0.0) 7 (3.2) 12 (9.0)
LAB alone 3 (9.1) 6 (2.7) 0 (0.0)
Aminophylline 2 (6.1) 8 (3.6) 3 (2.2)
Unknown 0 (0.0) 8 (3.6) 1 (0.7)
Others 1 (3.0) 5 (2.3) 4 (3.0)
CA: controlled asthma; PCA: partially controlled asthma; 
UA: uncontrolled asthma; IC: inhaled corticosteroid; and 
LAB: long-acting bronchodilator. aValues expressed as n (%).
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indicated by the name of the medication, showed 
that their rate of use, in the three groups, ranged 
from 66% to 80% (Table 4). This is another 
indication of underuse of maintenance medication, 
because it reflects the high number of patients 
who used rescue medication. This high rate of 
rescue medication use shows that patients were 
still having asthma attacks, suggesting that the 
doses of maintenance medication were insufficient. 
One limitation of the administered questionnaire 
in terms of short-acting bronchodilator use was 
that patients were asked solely whether they had 
or had not used the medication in the past four 
weeks, rather than being asked about the frequency 
of use. This information was partially taken into 
account when classifying asthma control.
Oral corticosteroid use, another marker of 
poor asthma control, shows a trend toward 
being increased in the partially controlled and 
uncontrolled asthma groups. The need for oral 
corticosteroid use, in all groups, was higher in 
Brazil than in the United States (controlled asthma, 
45.9% vs. 15%; partially controlled asthma, 
40.7% vs. 40%; uncontrolled asthma, 56.2% 
vs. 45%). (18) In 2009, a study of asthma education 
that was conducted in Brazil and followed patients 
over a two-year period reported an association 
between reduced oral corticosteroid use and 
increased compliance with maintenance treatment, 
emphasizing the importance of educational 
interventions for asthma control.(21)
It is of interest that the number of patients 
who reported having a written treatment plan in 
Brazil (41%) was higher than that in the United 
States (32%).(15) In the AIRLA survey,(12) in 2003, the 
observed proportion of adult patients who had a 
prepared action plan (38%) was very similar to the 
current number, which demonstrates that, despite 
the Brazilian Thoracic Association guidelines(2) 
and the GINA guidelines,(8) there has been no 
progress on this issue.
The design of the present study was the same 
as that of the AIM survey(16) and was similar to that 
of the AIRLA survey.(12) However, some limitations 
were found in our study. Only four Brazilian cities 
were assessed in the study, which means that the 
study sample may not be representative of the 
general population in Brazil. It is very difficult to 
cover the entire population of a country in studies 
with this type of design, though. Nevertheless, 
because each of the included cities is located in 
a different area of the country, this limitation 
compliant with maintenance therapy, which 
would demonstrate their poor understanding 
of the disease and its treatment. When asked 
whether they had some concern about using an 
inhaled corticosteroid continuously, 62.3% of the 
patients responded affirmatively, which shows us 
that most patients were not informed of or did 
not understand the importance of maintenance 
treatment of asthma. This demonstrates that 
greater educational intervention is needed to 
resolve patient uncertainties about the safety 
of the medication, its possible side effects, and 
its long-term benefits. Other factors that may 
explain the poor treatment compliance are poor 
symptom perception by the patients, difficult 
access to medical appointments, medication 
cost, and medication dose schedule.
A study conducted at a referral center for 
the treatment of severe asthma in the state of 
Bahia,(20) Brazil, in which educational strategies 
were used, reported high compliance with inhaled 
corticosteroid use (83.8%). This shows that the 
use of appropriate patient education strategies 
makes it possible to achieve optimal treatment. 
The factors related to patient noncompliance in 
that study were medication adverse effects, living 
far from the referral center, limited resources to 
pay for transportation to and from the center, 
and dose schedule.(20)
Analysis of Tables 3 and 4, which depict the 
medications reported by patients as being used, 
shows that there is clear confusion between 
maintenance and rescue therapy, i.e., patients 
have difficulty acknowledging the role of each 
type of therapy in the treatment of asthma. Some 
patients were using an inhaled corticosteroid 
alone for relief of symptoms. A cause for even 
greater concern is that there were patients 
(5.6% and 3.5% in the controlled and partially 
controlled asthma groups, respectively) who were 
using a long-acting β2 agonist alone, which is 
absolutely advised against in the treatment of 
asthma. Once again, the lack of understanding 
of the disease and its treatment on the part of 
patients is evident.
Rescue short-acting bronchodilator use is one 
of the markers of asthma severity, and, in the 
present study, the patients in greatest need for 
rescue medication use were found to be those in 
the partially controlled and uncontrolled asthma 
groups. An assessment of the medications used 
for relief of symptoms in the past four weeks, as 
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is mitigated. Another limitation was the fact 
that spirometry, a test that is also part of the 
criteria for asthma control, was not performed. 
However, given that the primary objective of the 
study was to characterize the reality of patients 
and their daily routine, classification of asthma 
control solely on the basis of the questionnaire 
responses was enough to show that the goal of 
attaining disease control has yet to be achieved 
in asthma management. Finally, the data on the 
diagnosis of asthma and the other data were 
obtained by self-report rather than from medical 
record abstraction.
On the basis of this study, we conclude that, 
in accordance with GINA criteria, asthma is not 
adequately controlled in the vast majority of 
asthma patients in Brazil, and this poor control 
should be attributed to underuse of maintenance 
medication. Consequently, we found that rescue 
medications and oral corticosteroids are very 
often used by patients with partially controlled 
or uncontrolled asthma. Therefore, greater efforts 
should be made to ensure that proper asthma 
treatment is prescribed and that compliance 
with the treatment plan is achieved.
References
1. Murphy KR, Meltzer EO, Blaiss MS, Nathan RA, Stoloff 
SW, Doherty DE. Asthma management and control in 
the United States: results of the 2009 Asthma Insight 
and Management survey. Allergy Asthma Proc. 2012; 
33(1):54-64. 
2. Sociedade Brasileira de Pneumologia e Tisiologia. 
Diretrizes da Sociedade Brasileira de Pneumologia e 
Tisiologia para o Manejo da Asma 2012. J Bras Pneumol. 
2012;38(Suppl 1) S1-S46.
3. Asher MI, Montefort S, Björkstén B, Lai CK, Strachan DP, 
Weiland SK, et al. Worldwide time trends in the prevalence 
of symptoms of asthma, allergic rhinoconjunctivitis, 
and eczema in childhood: ISAAC Phases One and Three 
repeat multicountry cross-sectional surveys. Lancet. 
2006;368(9537):733-43. http://dx.doi.org/10.1016/
S0140-6736(06)69283-0
4. Sole D, Wandalsen GF, Camelo-Nunes IC, Naspitz CK; 
ISAAC - Brazilian Group. Prevalence of symptoms of 
asthma, rhinitis, and atopic eczema among Brazilian 
children and adolescents identified by the International 
Study of Asthma and Allergies in Childhood (ISAAC) - 
Phase 3. J Pediatr (Rio J). 2006;82(5):341-6. http://
dx.doi.org/10.1590/S0021-75572006000600006
5. Amaral LM, Palma PV, Leite IC. Evolution of public 
policies and programs for asthma control in Brazil 
from the perspective of consensus guidelines. J Bras 
Pneumol. 2012;38(4):518-25. http://dx.doi.org/10.1590/
S1806-37132012000400015
6. Neffen H, Baena-Cagnani CE, Malka S, Solé D, Sepúlveda 
R, Caraballo L, et al. Asthma mortality in Latin America. 
J Investig Allergol Clin Immunol. 1997;7(4):249-53.
494 Marchioro J, Gazzotti MR, Nascimento AO, Montealegre F, Fish J, Jardim JR
J Bras Pneumol. 2014;40(5):487-494 http://dx.doi.org/10.1590/S1806-37132014000500004
About the authors
Josiane Marchioro
Pulmonologist. Federal University of São Paulo Paulista School of Medicine, São Paulo, Brazil.
Mariana Rodrigues Gazzotti
Professor. Federal University of São Paulo Paulista School of Medicine, São Paulo, Brazil.
Oliver Augusto Nascimento
Attending Pulmonologist. Federal University of São Paulo Paulista School of Medicine, São Paulo, Brazil.
Federico Montealegre
Medical Director. Merck, Sharp & Dohme Corp., São Paulo, Brazil.
James Fish
Global Scientific Affairs. Merck, Sharp & Dohme Corp., São Paulo, Brazil.
José Roberto Jardim
Tenured Professor of Pulmonology. Federal University of São Paulo Paulista School of Medicine, São Paulo, Brazil.
